NCT03294135View on ClinicalTrials.gov

The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine

PHASE4CompletedINTERVENTIONAL

Enrollment

194

Participants

Timeline

Start Date

October 5, 2017

Primary Completion Date

October 25, 2021

Study Completion Date

October 25, 2021

Conditions

Virus Diseases

Interventions

BIOLOGICAL

Encepur Adults

One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.

Trial Locations (1)

50002

GSK Investigational Site, Hradec Králové